CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Botulinum Toxin Type A +1 moredrug
Likely dose
Botulinum Toxin Type A 2.5 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01691651
NCT01691651N/ACompleted
CompareCT.gov

Botulinum Toxin Type A for Keratoconus

Federal University of São Paulo·interventional·Posted Sep 25, 2012·Updated Oct 21, 2014

In Brief

A clinical study evaluating Subcutaneous injection of botulinum toxin type A and Botulinum Toxin Type A for Keratoconus. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to associate the use of botulinum toxin type A for patients with keratoconus to demonstrate that tension eyelid has an important role in disease progression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKeratoconus
CountriesBrazil
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 25, 2012
Enrollment StartSep 1, 2012
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 13.8 years ago

Interventions

Subcutaneous injection of botulinum toxin type Aprocedure

Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.

Botulinum Toxin Type Adrug

2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.